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Association of multiple sclerosis (MS) with the human leukocyte antigen (HLA) class II haplotype DRB1*1501-
DQB1*0602 is the most consistently replicated finding of genetic studies of the disease. However, the high level
of linkage disequilibrium (LD) in the HLA region has hindered the identification of other loci that single-marker
tests for association are unlikely to resolve. In order to address this issue, we generated haplotypes spanning 14.754
Mb (5 cM) across the entire HLA region. The haplotypes, which were inferred by genotyping relatives of 152
patients with MS and 105 unaffected control subjects of Tasmanian ancestry, define a genomic segment from
D6S276 to D6S291, including 13 microsatellite markers integrated with allele-typing data for DRB1 and DQB1.
Association to the DRB1*1501-DQB1*0602 haplotype was replicated. In addition, we found that the class I/
extended class I region, defined by a genomic segment of ∼400 kb between MOGCA and D6S265, harbors genes
that independently increase risk of, or provide protection from, MS. Log-linear modeling analysis of constituent
haplotypes that represent genomic regions containing class I (MOGCA-D6S265), class III (TNFa-TNFd-D6S273),
and class II (DRB1-DQB1) genes indicated that having class I and class II susceptibility variants on the same
haplotype provides an additive effect on risk. Moreover, we found no evidence for a disease locus in the class III
region defined by a 150-kb genomic segment containing the TNF locus and 14 other genes. A global overview of
LD performed using GOLD identified two discrete blocks of LD in the HLA region that correspond well with
previous findings. We propose that the analysis of haplotypes, by use of the types of approaches outlined in the
present article, should make it possible to more accurately define the contribution of the HLA to MS.
Introduction
Multiple sclerosis (MS [MIM 126200]) is the most com-
mon neurological disease of young white adults of north-
ern European ancestry (prevalence 1:1,000). It is a
complex disease of the CNS of unknown etiology. Pop-
ulation-based studies indicate that familial aggregation
of MS is due to shared genetics (Ebers et al. 1995);
however, concordance studies in twins suggest that ge-
netic factors are not solely responsible for disease sus-
ceptibility (Ebers et al. 1986; Mumford et al. 1994).
Involvement of the HLA complex in susceptibility toMS
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was identified, through allelic association to HLA-A*03
(telomeric “classical” class I region), almost 30 years
ago (Jersild et al. 1972). Subsequently, the initial asso-
ciation with HLA-A*03 was shown to be secondary to
HLA-B*07 (centromeric “classical” class I region),
which, in turn, was shown to be in linkage disequilib-
rium (LD) with the class II alleles HLA-DR2 and
-DQw6. These serological typings have since been re-
fined to the DR15 and DQ6 subtypes of DR2 and
DQw6, respectively, which correspond to phenotypic ex-
pression of the DRB1*1501-DRB5*0101 (DR15) and
DQA1*0102-DQB1*0602 (DQ6) genotypes (Olerup
and Hillert 1991). More recently, the class I region has
been reidentified as harboring genes that independently
modulate susceptibility to MS (Fogdell-Hahn et al.
2000). Linkage and association studies of the HLA re-
gion have consistently supported the involvement of the
DRB1*1501-DRB5*0101-DQA1*0102-DQB1*0602
haplotype in susceptibility to MS, even in populations
of diverse ethnic origin. Indeed, recent work has indi-
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cated that a number of different clinical correlates are
associated with the DR2 susceptibility haplotype
(McDonnell et al. 1999; Celius et al. 2000; Masterman
et al. 2000). Nevertheless, the contribution ofHLAgenes
to MS susceptibility appears to be much less than in type
I diabetes; however, this may be difficult to quantify,
given the evidence of epistatic interactions betweenHLA
and non-HLA genes (Chataway et al. 1998).
There has been conjecture concerning the involve-
ment of the TNFa gene, which maps in the extended
haplotype defined by DRB1*1501-DQB1*0602 (Cor-
addu et al. 1998). Current theories on the mechanisms
of tissue injury in MS hint at a role for the TNFa gene
(telomeric class III region) in mediating the destruction
of oligodendrocytes by macrophages or microglia.
However, conflicting reports continue regarding its in-
volvement in an extended haplotype independent of the
HLA class II association (Roth et al. 1994; Allcock et
al. 1999; Fernandez-Arquero et al. 1999).
LD and variable rates of recombination are both rec-
ognized features of the HLA locus (Begovich et al. 1992;
Martin et al. 1995; Cullen et al. 1997). It has been
postulated that regions of the HLA that experience
lower recombination frequencies (stronger LD) may in-
dicate the existence of selective pressure to maintain
specific allelic combinations in cis. This could occur if
specific alleles at closely linked loci are selected for syn-
ergistic interactions. For example, it has been shown
previously that haplotypic association of specific DQA1
and DQB1 alleles ensures a functional heterodimer
(Kwok et al. 1993). Additional evidence of selection has
been provided by high-resolution typing of HLA class
I and II genes in CEPH families, showing the existence
of particular combinations of class I and class II alleles
(Bugawan et al. 2000).
The high level of LD in the HLA region has proven
to be a factor confounding to gene localization. Nev-
ertheless, analysis of ancestral haplotypes in the ex-
tended class I region of the HLA region was employed
to locate the HFE gene, mutant forms of which cause
hereditary hemochromatosis in 83% of affected indi-
viduals (Feder et al. 1996). Ancestral haplotype analysis
has also been employed to localize a susceptibility gene
(PSORSI) for psoriasis to a 60-kb region at the cen-
tromeric end of the class I region (Jenisch et al. 1998;
Nair et al. 2000). In addition, the critical region for
Behc¸et disease has been refined, by association analysis,
to a 46-kb interval centromeric of HLA-B (Ota et al.
1999). All of these studies provide valuable information
for future high-resolution association studies of marker
locations and LD patterns in different haplotypes.
We have recruited patients with MS from Tasmania,
an island state of Australia. Tasmania was colonized as
a penal settlement by the British in 1803. Free settlers
were also encouraged to migrate to Tasmania through
the early-to-mid–19th century, and convict transpor-
tation ceased in 1853. It is estimated that the subsequent
outward migration of large numbers of men—and the
relative deficit of women—meant that there were at
most 10,000 couples of childbearing age in Tasmania
in the mid-1800s. It is believed that these “founding
families” are responsible for ∼65% of the current res-
idents of Tasmania. Only modest immigration has oc-
curred in the last 150 years. This is supported by census
data from 1996 (Australian Bureau of Statistics), which
indicate that 180% of Tasmania’s current 470,000 res-
idents were born in Australia and that almost 90%were
born in Australia, New Zealand, Great Britain, and Ire-
land, suggesting that the population is relatively eth-
nically homogeneous. Tasmania’s founder effect is
documented through the study of a large kindred seg-
regating Huntington disease, which has been traced
back nine generations to the father of a female migrant
who came to Tasmania in 1842 and gave rise to 765
living descendents (Pridmore 1990). These and many
other features of Tasmania make it an attractive place
to study the genetics of complex disease.
To elucidate the involvement of the HLA complex in
MS, we have performed a comprehensive analysis of
haplotypes spanning the HLA region in Tasmanian pa-
tients with MS. Exploiting a variety of statistical tech-
niques, including log-linear modeling and two-point
and multipoint LD mapping, we have made advances
toward the characterization and identification of the
genetic determinants of susceptibility and protection
that exist for MS in the HLA region.
Material and Methods
Inferring Haplotypes
Several methodologies permit the derivation of hap-
lotypes. We chose to use a constellation of close relatives
to infer phase—and hence haplotypes—probabilistically.
This method, although expensive in terms of genotypes,
has a number of beneficial consequences. First, the ge-
notyping of close relatives of a case or control subject,
makes it possible to check Mendelian errors, which can
identify pedigree and genotyping errors. Second, geno-
typing information from a number of close relatives ren-
ders the sample sufficiently versatile for use with other
genetic mapping techniques. Simulation studies per-
formed prior to recruitment indicated that two scenarios
provided excellent haplotype reconstruction (data not
shown). Genotyping of samples from both parents was
common to both scenarios; however, in one scenario, a
grandparent was also genotyped, and, in the other, two
siblings were the source of additional phase information.
In general, relatives in later generations yielded little
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phase information. Recruitment strategies were based on
the findings of these simulation studies.
Case Subjects
The Tasmanian MS Research Program was approved
by the University of Tasmania’s human research ethics
committee, and written consent was obtained from all
participants. The program was advertised in local news-
papers, radio stations, and in regular newsletters sent to
patients with MS by the Multiple Sclerosis Societies of
Tasmania and Victoria. Patients with MS were self-
referred volunteers, and possession of at least one Tas-
manian-born grandparent was a key selection criterion.
Information was recorded concerning immediate family
history of disease and living close relatives. Recruitment
of relatives was prioritized as (in order of preference):
parents, grandparents, siblings, spouses, and offspring.
We also identified, with the assistance of the MS Society
of Victoria, 26 Tasmanian migrants with MS living in
Victoria, Australia, who met the recruitment criteria.
Control Subjects
We asked case subjects to nominate control subjects,
to maximize matching for age, ethnicity, geographic or-
igin, and socioeconomic background. This approach
was taken in order to increase the chances of recruiting
close relatives of the control subjects, which was deemed
more likely to succeed if the control had a (nongenetic)
relationship to the case. Moreover, these control subjects
would be more likely to match closely the ancestral back-
ground of the patient. When case patients were unable
to nominate a person to act as a control, control subjects
matched on the basis of age and sex were recruited from
the Tasmanian electoral roll.
Clinical Diagnosis
The treating doctors of patients who registered an
interest in participating in the present study were asked
to complete a confidential medical record summary.
They were asked whether they considered the patient to
have clinically definite, laboratory-supported definite,
clinically probable, or laboratory-supported probable
MS or, alternatively, to have no or, at most, only possible
MS, according to the diagnostic criteria defined by Poser
et al. (1983). Subsequent to this, all respondents were
interviewed and examined by one of the six participating
neurologists. In addition, when available, magnetic res-
onance imaging (MRI) results were assessed or, at a min-
imum, MRI reports were obtained. The Poser criteria of
clinically definite or laboratory-supported definite MS
were set as the minimum standard by which patients
were included in the study, but, in addition, patientswere
required to have cerebral MRI abnormalities consistent
with MS, as defined by the criteria of Paty et al. (1988).
All patients with a classification of primary progressive
MS had to exhibit progressive neurological disability for
at least one year, to have no other better explanation
for the clinical features, and to have not only relevant
spinal cord abnormalities but also changes on cerebral
MRI consistent with demyelination.
DNA Preparation and Genotyping
DNA was extracted from peripheral blood, using a
Nucleon extraction kit according to the manufacturer’s
instructions. Genomic DNA was resuspended in 10 mM
Tris-HCl (pH 8), 1 mM EDTA (pH 8) and was stored
at 4C. PCR was performed, according to published con-
ditions, on 30 ng of genomic DNA by use of AmpliTaq
Gold at the Australian Genome Research Facility
(AGRF). At the AGRF, genotyping was performed on
DNA samples from the case and control subjects and
from selected family members, using ABI-Prism 377 se-
quencing machines. Dye-labeled PCR products were de-
tected using GENESCAN (PE Applied Biosystems)
software, and allele calling was performed using GEN-
OTYPER 2.0 (PE Applied Biosystems). Initial error anal-
ysis on genotypes was performed as described elsewhere
(Ewen et al. 2000).
Simple Sequence-Length Polymorphism Markers
Oligonucleotide primers corresponding to simple
sequence-length polymorphisms (SSLPs) for D6S105,
MOGCA, D6S265, D6S273, G51152, and RING3CA
were designed according to Martin et al. (1998). Primers
for D6S276 and D6S291 were obtained from the HD-
5 fine-mapping set (PE Applied Biosystems). Primers for
D6S1571, D6S1568, D6S439, TNFa, and TNFd were
designed according to sequence published by Foissac et
al. (2000) and the Genome Database (GDB). Genetic
and physical distances between genes and markers were
obtained from The National Center for Biotechnology
Information, the GDB, and the University of California,
Santa Cruz, Human Genome Working Draft. Forward
primer sequences of these markers were “pig-tailed”
with a heptanucleotide (5′-GTTTCTT-3′) sequence, to
facilitate genotyping by minimizing the effects of
enzyme-directed, template-independent additions of an
“A” nucleotide to PCR products.
HLA Typing
HLA-DRB1 and DQB1 allele typing was performed
using methods outlined in the 11th International His-
tocompatibility Workshop (Kimura and Sasasuki 1991).
In brief, exon 2 polymorphisms were determined by use
of a series of biotinylated oligonucleotide probes that
were hybridized to PCR-amplified DNA immobilized on
nylonmembranes. Complementary probeswere detected
using a streptavidin–alkaline phosphatase conjugate and
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the chemiluminescent substrate CDP-Star (Roche Di-
agnostics PTY). For each locus, new probes and primers
were added to cover sequence polymorphisms not de-
scribed in the original protocol.
Haplotype Reconstruction
Genotyping errors were detected using PedCheck
(O’Connell and Weeks 1998). Inconsistent data were
either corrected or deleted. File management of the data,
pedigree, and map distance information was performed
using an in-house program, LINKPREP, to generate
LINKAGE style “.dat” and “.pre” files.GENEHUNTER
(Kruglyak et al. 1996) was used to reconstruct inferred
haplotypes, which were extracted from the GENE-
HUNTER output file, haplo.dump, using an in-house
PERL script, HAPLO.PL. This program separates case
and control haplotypes, and calculates the allele fre-
quencies and counts used in the CLUMP program (Sham
and Curtis 1995).
Statistical Analysis
Association tests for single markers were performed
using CLUMP (Sham and Curtis 1995) with the T4 sta-
tistic being chosen as the test statistic for association.
The T4 statistic calculates the maximum x2 value found
by collapsing the contingency table over each allele in
turn, forming contingency tables and combining2# 2
alleles whenever allele counts are too small. The distri-
bution of this statistic is not distributed as variable2x1
and its significance must be assessed through the use of
Monte Carlo methods, which is how the P values were
calculated using CLUMP.
Haplotypes were assessed using odds ratios (ORs) and
were calculated using the statistical software R. All hap-
lotypes can be defined as either showing a susceptibility
or protective effect. Hence, all ORswere calculated using
the appropriate one-sided test for the contingency2# 2
table. The general linear modeling function of Splus5
was used to assess the effects of LD, disease-haplotype
interactions and haplotype-haplotype interactions. Mul-
tiple testing was corrected for 22 tests, 7 examining the
tables and 15 examining the T4 statistic from2# 2
CLUMP. Pairwise LDwas assessed for cases and controls
using the Global Overview of Linkage Disequilibrium
(GOLD) program (Abecasis and Cookson 2000).
Results
Recruitment
A total of 222 patients were assessed, and 181 of these
were admitted to the study, after application of the cri-
teria described above. When all relevant data had been
compiled and assessed, the final decision concerning in-
clusion was based on the consensus opinions of two
physicians specializing in MS (T.J.K. and H.B.). Of the
41 patients excluded from the study, 17 had normal,
nondiagnostic, or atypical MRI results or had not had
an MRI performed; 8 had monophasic disease; 7 had
other neurological disorders (1 spinocerebellar atrophy,
1 Devic disease, 1 cerebral autosomal dominant arte-
riopathy with subcortial infarcts and leukoencephalo-
pathy, 1 syringomyelia, and 1 Leber optic atrophy); 2
had connective tissue disorders; 2 had musculoskeletal
disorders; 4 had functional disorders; and 1 patient
asked to be excluded.
In total, 181 case subjects and 843 of their close rel-
atives (an average of 4.7 controls per case) were re-
cruited. The present article describes data for 152 case
subjects only. Sample collection for the remaining 29
case families is in progress. Despite the fact that the
average age of case subjects was 45.9 years, most of the
relatives recruited were in the “highly informative” cat-
egory (parents, grandparents, and siblings), rather than
spouses and offspring.
Nonbiological relatives (44% spouses and 5% in-
laws) accounted for approximately half the control co-
hort, with friends (18%) and locally selected individuals
from the electoral roll (33%) representing the remainder.
All control subjects had no family history of MS and
had at least one grandparent born in Tasmania. In total,
samples for 105 control subjects and 400 of their close
relatives were collected.
Assessment of Haplotype Reconstruction
We designed a recruitment strategy for close relatives
of case and control subjects that would permit the re-
construction of haplotypes. Haplotypes were inferred
from familial genotyping data, using GENEHUNTER
(Kruglyak et al. 1996). Genotyping was performed for
152 case and 105 control subjects and their correspond-
ing relatives. Haplotypes were generated across the HLA
region for 15 markers, corresponding to 13 SSLP mark-
ers and allele typing data for the DRB1 and DQB1 genes
(fig. 1). These markers span the HLA region from
D6S276 to D6S291, which corresponds to a genetic dis-
tance of 5 cM and a physical distance of 14.754 Mb.
To gauge the success of the recruitment strategy, we cal-
culated the proportion of haplotypes that would be re-
constructed, in theory, if recruitment were “perfect” and
compared it with the observed proportion of haplotypes
reconstructed. For cases, 292 haplotypes were inferred
(96% of the theoretical maximum [304]); and, for con-
trols, 204 haplotypes were inferred (97% of the maxi-
mum [210]).
CLUMP Analysis of Allele Frequencies
Allelic association was performed using the T4 sta-
tistic in CLUMP (Sham and Curtis 1995) (table 1). The
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Table 1
Allele Frequencies in Cases versus Controls
Marker
No. of
Alleles T4a P
Corrected
Pb
D6S276 14 6.5 .5 1.0
D6S105 12 18.4 .003 .07
MOGCA 13 29.2 1 # 105 2 # 104
D6S265 11 14.1 .009 .2
D6S1571 11 13.8 .01 .2
D6S1568 11 5.4 .7 1.0
TNFa 14 20.6 .002 .04
TNFd 8 5.3 .2 1.0
D6S273 8 4.7 .4 1.0
DRB1 15 32.4 !1 # 105 !2 # 104
DQB1 11 34.1 !1 # 105 !2 # 104
G51152 10 35.8 !1 # 105 !2 # 104
RING3CA 8 1.6 .9 1.0
D6S439 11 14.5 .009 .2
D6S291 6 1.1 .9 1.0
NOTE.—Comparisons were performed using CLUMP
(Sham and Curtis 1995).
a The T4 measure was determined with 100,000 sim-
ulations of the data for all 15 markers, and the corre-
sponding P value was calculated.
b The corrected P value was determined by multiplying
the uncorrected P value by the number of tests displayed
in this table added to those displayed in table 2 (22 tests
overall).
Figure 1 An integrated physical map of the HLA region, showing the locations of the 13 SSLP markers: pTer-D6S276, D6S105,MOGCA,
D6S265, D6S1571, D6S1568, TNFa, TNFd, D6S273, G51152, RINGCA, D6S439, and D6S291-cen. Selected genes (not drawn to scale)
involved in functions of the immune system are represented by hatched boxes. The boundary between the “extended” and “classical” class I
region lies between MOGCA and HLA-F. The “classical” class I region extends 1.8 Mb centromeric of HLA-F. The telomeric boundary of the
class III region lies between HLA-B and the TNF locus. The class III region extends 0.75 Mb to the centromeric boundary with class II, which
is located between D6S273 and DRA. The “classical” class II region extends 0.85 Mb, just centromeric of DPB1. This physical map was
assembled with information from a number of sources (MHC Consortium 1999; Foissac et al. 2000; National Center for Biotechnology
Information).
P value for each marker was evaluated using 100,000
Monte Carlo simulations. Prior to correction for mul-
tiple testing (22 tests performed [see tables 1 and 2]),
significantly associated markers were found in the ex-
tended class I (D6S105 and MOGCA), classical class I
(D6S265 and D6S1571), class III (TNFa), class II
(DRB1, DQB1, and G51152), and extended class II
(D6S439) regions (table 1). After multiple testing was
taken into account, only MOGCA ( ),4Pp 2# 10
TNFa ( ), DRB1 ( ), DQB1 (4Pp .04 Pp 2# 10 Pp
), and G51152 ( ) remained sig-4 42# 10 Pp 2# 10
nificantly associated.
Analysis of Haplotype Frequencies
Since the HLA region is characterized by high levels
of LD, we analyzed a subset of those markers showing
evidence of association with MS as haplotypes rather
than as single markers (fig. 2A–C). To allow a compar-
ison with other studies, the haplotypes studied in more
depth corresponded to regions of the HLA complex pre-
viously identified as harboring determinants of disease
susceptibility. SSLP markers 400 kb apart selected for
haplotype analysis of the class I region were MOGCA
(upstream of the MOG gene, 100 kb telomeric of HLA-
F) and D6S265 (70–100 kb centromeric of HLA-A). For
the class III region, the SSLP markers TNFa (3.5 kb
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Table 2
Statistical Analysis of Haplotype Frequencies
Haplotypea
HLA
Class Effectb P Corrected Pc OR (95% CI)d
3-1-#-#-#-#-# I S 3 # 105 7 # 104 3.1 (1.8, )
12-3-#-#-#-#-# I S .09 1 1.5 (.9, )
1-6-#-#-#-#-# I P .001 .03 .3 (.0, .6)
4-5-#-#-#-#-# I P .06 1 .7 (.0, 1.0)
#-#-11-4-5-#-# III S 7 # 105 .002 2.8 (1.7, )
#-#-2-5-5-#-# III P .01 .3 .4 (.0, .8)
#-#-#-#-#-14-12 II S 5 # 109 1 # 107 4.3 (2.7, )
a Haplotypes were stratified for analysis on the basis of results shown in figure 2.
Class I, III, and II loci were analyzed independently in cases versus controls, with the
presence of any allele at other loci signified by “#.”
b S p susceptibility; P p protective.
c The corrected P value was determined by multiplying the uncorrected P value by
the number of tests displayed in this table added to those displayed in table 1 (22 tests
overall). Each corrected P value has been adjusted for 22 tests, as in table 1.
d All ORs were calculated using all other haplotypes as the reference group or using
one-sided tests, depending on whether the haplotype conferred putative susceptibility or
protective effects.
telomeric of lymphotoxin, TNFd (8 kb downstream of
TNFa), and D6S273 (exon 2 and exon 3 of G6D, 150
kb centromeric of the TNF locus) were chosen (Jonge-
neel et al. 1991; Udalova et al. 1993; Foissac et al. 2000).
Although D6S265, TNFd, and D6S273 were not sig-
nificantly associated alone, they permit the analysis of
genomic segments that harbor a number of genes in-
volved in the function of the immune system. Class II
haplotypes were defined by polymorphisms in the DRB1
and DQB1 genes. Allele binning information formarkers
described in figure 2A–C can be found in the Appendix.
Forty-two haplotypes were counted in cases and con-
trols for the class I (MOGCA-D6S265) region. For ease
of presentation—and because we did not have sufficient
power to evaluate differences in frequency between rare
haplotypes—only those with a frequency 1% were
compared (fig. 2A). A susceptibility haplotype, 3-1, was
observed with a frequency of 21.5% in cases and 8.2%
in controls. Because the HLA-A gene is flanked distally
by MOGCA and proximally by D6S265, we tested
whether case and control samples carrying the 3-1 sus-
ceptibility haplotype were also carrying the HLA-A*03
allele. Twenty-one cases carrying the 3-1 haplotype were
tested for the presence of an HLA-A*03 allele (data not
shown). All samples tested positive for HLA-A*03. Since
the A*0301 allele comprises 99% of all A*03s, which
have a population frequency of ∼20%, there is strong
evidence to suggest that the 3-1 haplotype in this sample
corresponds to the same ancestral susceptibility haplo-
type described recently in Scandinavian patients withMS
(Fogdell-Hahn et al. 2000). Haplotypes in which dis-
crepancies in frequency between cases and controls pro-
vided evidence for additional effects on susceptibility
(12-3) and protection (1-6 and 4-5) were selected for
statistical analysis.
Overall, 97 different three-marker haplotypes were re-
corded for the class III (TNFa-TNFd-D6S273) region.
The larger number of haplotypes observed for class III
than for the class I region is a result of the additional
marker used to define a three- instead of a two-marker
haplotype. The majority (86) of these haplotypes had a
frequency !2%. Again, only the more common haplo-
types (frequency 2%) were compared between cases
and controls (fig. 2B). The 11 haplotypes analyzed in-
dividually represent 65.0% and 59.5% of case and con-
trol haplotypes, respectively. A putative susceptibility
haplotype, 11-4-5, with a frequency of 22.3% in cases
and 9.9% controls, was observed; and a putative pro-
tective haplotype, 2-5-5, with a frequency of 5.1% in
cases and 10.7% in controls, was also a notable finding
at this locus.
HLA class II (DRB1-DQB1) haplotypes with a fre-
quency 1% were analyzed in cases and controls (fig.
2C). Only the 14-12 haplotype (DRB1*1501-
DQB1*0602) differed markedly in frequency between
cases (31.5%) and controls (11.0%). The phenotypic
frequency of the DRB1*1501-DQB1*0602 haplotype
among cases (57.7%, ) and controls (22%,np 142
) was similar to other populations of northernnp 95
European ancestry (Francis et al. 1991; Hillert and Ole-
rup 1993).
Statistical Analysis of Haplotype Frequencies
For the loci described above, a subset of seven hap-
lotypes were selected for further analysis. Previous stud-
ies guided us in our choice of haplotypes that were rel-
atively common and that showed the greatest disparity
between cases and controls. Therefore, we believe that
those haplotypes that account for the greatest disease
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Figure 2 Comparison of haplotype frequencies between case and
control subjects. For the class I region (A), MOGCA-D6S265 haplo-
types were analyzed; for the class III region (B), TNFa-TNFd-D6S273
haplotypes were analyzed and for the class II region (C), DRB1-DQB1
haplotypes were analyzed. Haplotypes with a frequency of 1% in
cases and controls were plotted for MOGCA-D6S265 and DRB1-
DQB1, but only haplotypes with a frequency 2% were plotted for
TNFa-TNFd-D6S273. Coding of haplotypes is describe in the Appen-
dix. Asterisks (*) indicate haplotypes selected for association testing.
risk have been selected for further analysis. Nevertheless,
although it is unlikely that we have missed high-risk
haplotypes, the possibility remains.
For the class I region, four haplotypes with putative
susceptibility (3-1 and 12-3) or protective (1-6 and 4-5)
effects were chosen. Two haplotypes were analyzed fur-
ther for the class III region (11-4-5 and 2-5-5), and only
the 14-12 (DRB1*1501-DQB1*0602) haplotype was se-
lected from class II haplotypes (table 2). Given that the
true MS susceptibility loci and/or the main susceptibility
haplotype(s) were unknown, there was no natural ref-
erence point to which other putative risk haplotypes
could be compared. Hence, ORs and Fisher’s exact test
for association were calculated from the number of hap-
lotypes for the seven “sub-haplotypes” that were pre-
selected, and ORs were calculated relative to all other
haplotypes. For the class I region, the 3-1 haplotype was
found to be significantly associated with disease suscep-
tibility ( ), whereas the 1-6 haplotype was4Pp 7# 10
borderline protective . The 11-4-5 haplotypePp .03
from the class III region ( ) and 14-12 from thePp .002
class II region (DRB1*1501-DQB1*0602, Pp 1#
) were significantly associated with disease suscep-710
tibility after correction for multiple testing (table 2).
We recognize that preselecting the most-discordant
haplotypes visually (fig. 2A–C) represents, in itself, a
form of statistical testing and, as such, these tests should
be corrected for. However, many of the tests are highly
correlated, and it is unclear what multiple-test correction
is appropriate. Bonferroni correction represents the
strongest form of statistical correction, since all tests are
assumed to be independent; however, no impact on the
major significant results in tables 1 and 2 occurred when
a correction for more tests was performed (data not
shown).
Log-Linear Modeling of Haplotype Interaction
The haplotype most associated with MS from each
locus was selected for further analysis to determine their
mode of interaction. The model included terms to de-
scribe association with disease, and LD between hap-
lotypes. The data for cases and controls were stratified
according to the most significantly associated haplo-
types, 3-1 (class I), 11-4-5 (class III), and 14-12 (class
II), producing a (four-way) contingency2# 2# 2# 2
table (tables 3 and 4) with three factors (the haplotypes)
and one response variable (affected or unaffected). Each
factor had two levels: having the haplotype or not having
the haplotype. Haplotypes with missing data at one or
more loci were excluded from the analysis, reducing the
data set to 276 case haplotypes and 190 control hap-
lotypes. The log-linear model was fitted using iterative
proportional fitting from several different models, such
as a saturated model (by deleting terms) and a main-
effects–only model (by adding terms). The same final
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Table 3
Log-Linear Modeling Analysis of Haplotypes
SUBJECT, HAPLOTYPE,
AND CONSTITUENT
HAPLOTYPE
NO. OF HAPLOTYPES
OBSERVED (EXPECTED) FOR
14-12 Not 14-12
Case, 11-4-5:
3-1 26 (27.8) 7 (6.4)
Not 3-1 25 (22.6) 4 (5.5)
Case, not 11-4-5:
3-1 6 (5.4) 22 (21.4)
Not 3-1 33 (34.2) 153 (152.7)
Control, 11-4-5:
3-1 5 (3.2) 2 (2.6)
Not 3-1 4 (6.4) 7 (5.5)
Control, not 11-4-5:
3-1 0 (.6) 8 (8.6)
Not 3-1 11 (9.8) 153 (153.3)
NOTE.—The table combines the four-way contingency tables that
were constructed to explore the relationship between the constituent
haplotypes 3-1 (MOGCA-D6S265: class I), 11-4-5 (TNFa-TNFd-
D6S273: class III) and 14-12 (DRB1-DQB1: class II). Only complete
haplotypes (276 case and 190 control) with no missing data at any of
the loci tested were included in the analysis.
Table 4
Summary of Class I (3-1) and Class II (14-12) Haplotype
Frequencies in Cases versus Controls, from the Log-Linear
Modeling Analysis
Constituent
Haplotype No. of Cases (%) No. of Controls (%)
3-1 and 14-12 32 (11.2) 5 (2.6)
3-1 and not 14-12 29 (10.5) 10 (5.3)
Not 3-1 and 14-12 58 (21.0) 15 (7.9)
Not 3-1 and not 14-12 157 (56.9) 160 (84.2)
fitted model was always reached, regardless of the start-
ing-point model: m dis h1412 h1145 h31
dis • h31 dis • h1412 h31 • h1145 h1145 • h1412
For the expected cell frequency, m is the grand mean,
dis represents the explanatory variable describing the
disease, and h31, h1412, and h1145 represent the three
susceptibility haplotypes. The factors separated by “•”
represent the interaction terms. Since the haplotypes
were treated as factors, it is prudent to fix their margins
(Plackett 1981). This is achieved by fitting the
h1412*h1145*h31 term in the final model. This term
represents the one-way, two-way, and three-way inter-
actions of the haplotypes, independent of disease, and
thus absorbs the background LD present in the popu-
lation. The final model gave a residual deviance of 4.9
with 5 df, which resulted in an excellent fit to the ob-
served haplotype counts (table 3). Dropping either of
the two significant haplotype disease interactions re-
sulted in highly significant changes of deviance, DD,
which is asymptotically distributed . For h1412,DDp2x1
24.1 ( ) and for h31, DD p 9.1 (6Pp 2# 10 Pp
). Plotting the residuals using a Q-Q plot indicated.001
that the main features of the data had been adequately
captured by the fitted model (data not shown).
Several conclusions can be drawn from the fitted
model. First, in the absence of disease status, exami-
nation of the one-, two-, and three-way interactions re-
vealed significant interactions between only immediately
adjacent haplotypes. The two terms describing the in-
teraction between h31 and h1412 and the three-way
interaction with the disease phenotype are not significant
(data not shown) and are only included in the model in
order to fix the margins. This does not mean that LD
does not spread over all three haplotypes; rather, the
neighboring haplotypes explain most of the LD in the
log-linear model. Log-linear modeling performed with
only the two flanking haplotypes (h1412 and h31)
showed a significant LD interaction (data not shown).
Second, the 11-4-5 haplotype (h1145) is not associated
with disease. This suggests that the TNF locus and 14
other expressed class III genes within this haplotype
(MHC Consortium 1999) are not associated with MS
per se but instead are associated by virtue of their tight
LD with the class II–associated susceptibility haplotype,
h1412 (DRB1*1501-DQB1*0602). Third, 3-1 (h31)
and 14-12 (h1412) show no higher-order interactions
with MS, implying that the haplotypes act additively as
independent susceptibility factors and therefore do not
interact multiplicatively. It is possible that there are
higher-order interactions between h31 and h1412; how-
ever, because these are not detectable with this data set,
these effects would be weak.
Two-Point LD Analysis
The haplotype data were subjected to two-point LD
analysis producing a global overview of LD, using the
D′ measure implemented in GOLD (fig. 3) (Abecasis and
Cookson 2000). GOLD uses the multiallelic D′ measure,
as defined by Hedrick (1987), which is a weighted av-
erage of the more familiar biallelic D′ measure. The
blocklike structure of LD within HLA is profound for
both cases and controls, with two discrete regions dis-
playing elevated levels of suppressed recombination. The
LD plots for case (fig. 3A) and control (fig. 3B) data are
very similar, with the D′ global maximum only slightly
higher in cases (0.87) than controls (0.84). Given the
differences in sample size, small differences of this nature
would be expected. The global and intrablock patterns
of LD are virtually identical in cases and controls, which
is a predictable result, given that we did not examine
LD surrounding particular haplotypes but rather overall
LD in the two samples. The distal block of LD in case
haplotypes extends ∼3 Mb centromeric of D6S105 (ex-
tended class I), to D6S1571 (classical class I) (fig. 1).
The local D′ maximum (0.63–0.71) in the region is lo-
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Figure 3 Two-point LD analysis, using GOLD, for case (A) and
control (B) haplotypes. The relative location of markers used to con-
struct the haplotypes is represented on the X-axis but is more clearly
depicted in figure 1. The X-axis has been rotated left through 90 for
the Y-axis, with the ticks identifying the relative marker location for
both axes. The LD measure, D′, is graphically represented adjacent to
each GOLD plot. For cases, D′ values are 0.07–0.87, and, for controls,
they are 0.09–0.84. Between the top and bottom D′ value, the range
has been divided into 10 intervals, each represented by a colored box.
The D′ value delineating each interval is indicated.
cated between MOGCA and D6S265. Centromeric of
D6S1571, a region of reduced LD extends to the TNF
locus. The level of LD then gradually increases from
TNFa to the DRB1-DQB1-G51152 haplotype, which
defines the location of the global and local D′ maximum
of 0.87 in case and control haplotypes. Centromeric of
this haplotype towards RING3CA, the level of LD de-
creases; however, even at this marker, D′ is 0.31–0.39.
Discussion
In the absence of genotypes from isolated chromosomes,
one relies on algorithms to infer haplotypes. These can
either derive probability distributions for potential hap-
lotypes, such as the expectation-maximization algorithm
(Slatkin and Excoffier 1996), or treat the haplotypes as
variables to be estimated using the genotypic data from
family members. One example of the latter method is
an application of the Hidden Markov Model (HMM)
that is known as the Lander-Green algorithm, in the
GENEHUNTER program (Kruglyak et al. 1996). We
have used this method for inferring haplotypes; however,
a caveat when using haplotypes inferred by GENE-
HUNTER is that the program returns only the haplotype
that maximizes the likelihood of the observed data, given
a specific marker map. It may be the case that there are
several possible haplotypes of equal or very close prob-
ability. Other algorithms—for example, a Monte Carlo
Markov chain approach, as implemented in
SIMWALK—
may yield different haplotypes. To date, we have used
only GENEHUNTER, which uses the Viterbi algorithm
from the HMM methodology (Rabiner 1989) to recon-
struct haplotypes; however, we anticipate that by ge-
notyping a constellation of close relatives, we can obtain
phase information that would be sufficient to permit
alternate algorithms to infer identical haplotypes inmost
families. In the future we plan to investigate haplotype
reconstruction qualitatively for these different algo-
rithms on genomewide data from this sample.
We have found susceptibility and protective haplo-
types in the class I region independent of the class II
susceptibility haplotype, DRB1*1501-DQB1*0602,
which replicated the findings of a recent study in dif-
ferent populations of northern European ancestry (Fog-
dell-Hahn et al. 2000). In addition, we have shown that
the TNF locus and 14 other genes delineated by a 150-
kb haplotype (TNFa-D6S273) in the class III region are
not involved in susceptibility to MS in this sample.
HLA-A typing of a number of affected individuals
provided strong evidence that the significantly associ-
ated class I susceptibility haplotype (3-1) was defined
by the presence of the A*0301 allele. However, we
found that the class I susceptibility haplotype had no
higher order interactions with the class II region but
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yielded an additive effect on risk, in contrast to recent
findings (Fogdell-Hahn et al. 2000). Nevertheless, these
results do not provide sufficient resolution to identify
the HLA-A*0301 allele as the causative susceptibility
determinant in this region of the HLA complex. Indeed,
speculating on the involvement of the HLA-A*0301
gene product on the basis of these results and allelic
typing of the HLA-A gene would be premature.
Lie and colleagues (1999) recently reported the map-
ping of an unidentified gene in the extended class I re-
gion that modulates susceptibility to type 1 diabetes and
celiac disease. We also identified a protective influence
of the class I region, defined by a MOGCA-D6S265
haplotype (1-6). It is unclear at present whether this
haplotype corresponds to the HLA-A*0201 allele de-
scribed recently in Swedish and Norwegian patients
with MS (Fogdell-Hahn et al. 2000). We did not analyze
this haplotype for interactions with the class II region,
because it was only weakly associated after correction
for multiple testing. Nevertheless, it remains to be rec-
ognized that while genetic variants conferring protec-
tion and susceptibility can be detected by association
with allelic variants of the HLA-A gene and the encom-
passing 400-kb haplotype, it is impossible to say at this
stage if allelic heterogeneity at the same locus is re-
sponsible. Moreover, it is not even clear if these variants
reside within the MOGCA-D6S265 haplotype. In ad-
dition, there were other MOGCA-D6S265 haplotypes
showing marginal evidence for association prior to cor-
rection for multiple testing. It is possible that these mar-
ginally associated haplotypes would, with a larger data
set, reach significance. Hence, it is intriguing to spec-
ulate that this region of the HLA complex contains mul-
tiple genetic determinants that play a role in MS.
By comparing two-point LD analyses of case and con-
trols haplotypes across the HLA region, a consistent
block-like pattern of LD was observed. These findings
correspond well with previous studies of recombination
rates in the HLA region (Martin et al. 1995; Cullen et
al. 1997; Bugawan et al. 2000). The centromeric block
of LD spanning class III and class II has long provided
a source of confusion for single-marker association
studies that use polymorphic markers in close proximity
to the TNF locus. In the present study we have been
able to dissect away a region of class III, including the
TNF locus, from involvement in MS. Recent studies of
recombination hot spots (Jeffreys et al. 2000, 2001) in
the class II region are supported by the erosion of LD
centromeric of the DRB1 gene. Efforts aimed at cloning
the gene responsible for hemochromatosis (Feder et al.
1996) in 83% of patients were hindered by the strong
LD extending almost 3.8 Mb telomeric of the HLA-A
gene.
The HLA region contains genes that contribute to
susceptibility and provide protection fromMS. In order
to conduct a genetic dissection of the HLA region that
will help to identify the causative variants, it will be
necessary to employ approaches that utilize haplotype
information. Testing haplotypes rather than single loci
provides the advantage of being able to test genomic
segments encoding multiple genes, which represents a
way to help distinguish true association from the con-
founding effects of strong LD. Interaction betweenHLA
genes in trans is documented for type 1 diabetes and is
therefore possible in MS. Hence, although the present
article addresses haplotype interactions in cis, analyses
of interactions in trans are warranted, but we recognize
that a larger data set may be required to afford sufficient
power for such a study. By analyzing haplotypes
through the use of the approaches outlined here, we
should gain a better understanding of the way in which
the HLA region modulates disease.
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Appendix
Table A1
Allele-Coding Information for Seven Markers in the HLA Region
Allele MOGCA D6S265 TNFa TNFd D6S273 DRB1* DQB1*
1 121 174 104 129 146 01/0103 0301
2 127 176 106 131 149 02 0302
3 129 178 108 133 151 03 0303
4 131 180 110 135 152 04 0304
5 133 182 112 137 154 06 0305
6 135 184 114 139 156 07 0402
7 137 186 116 141 158 08 0501
8 139 190 118 143 160 09 0502
9 141 192 120 … … 10 0503
10 143 194 122 … … 11 0504
11 146 196 124 … … 12 0601
12 148 … 126 … … 13 0602
13 150 … 128 … … 14 0603
14 152 … 130 … … 1501 0604
15 … … … … … 1502 0201/0202
16 … … … … … 1601 0605/0609
NOTE.—Except for allelic designation for the DRB1 and DQB1 genes, all “raw”
allele data for SSLP markers (MOGCA, D6S265, TNFa, TNFd, and D6S273) are in
base pairs. The degree to which allelic typing of the DRB1 andDQB1 genes was resolved
was not uniform over all alleles, because prior knowledge existed for association.Hence,
we pursued the resolution of DRB1*15, DRB1*16 and DQB1*06 genotypes. For in-
stance, the DRB1*01 (allele 1) typing corresponds to multiple alleles, including
DRB1*0103, which have not been resolved. When the population frequency of a par-
ticular allele was not split and was not strongly biased (190%) in favor of one allele,
both alleles have been recorded as possible (e.g, 0201/0202 and 0605/0609).
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